Summary
The pharmaceutical development of the investigational cytotoxic drug EO9 included the structural characterization of the bulk drug by nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS) and infrared (IR) spectroscopy, and analytical characterization by high-performance liquid chromatography and ultraviolet/visible spectrophotometry. The presence of impurities in the bulk drug was investigated. The intermediates in the synthesis of EO9 were structurally characterized by NMR spectroscopy and MS, and analytically characterized by HPLC analysis with photodiode array (PDA) detection. All of the intermediates were below their limits of detection in EO9 bulk drug. The amounts of residual organic solvents were determined by gas chromatography. Methanol and ethanol were detected, but the amounts present did not exceed the limits as set in the United States Pharmacopeia XXII.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Winograd B, Lobbezoo MW, Double JA, Fiebig HH, Lelieveld P, Workman P, Pinedo HM: Preclinical antitumor profile of EO9, a novel bioreductive alkylating indoloquinone derivative. Proc Am Assoc Cancer Res 30:582, 1989
Hendriks HR, Pizao PE, Berger DP, Kooistra KL, Bibby MC, Boven E, Dreef-van der Meulen HC, Henrar REC, Fiebig HH, Double JA, Hornstra HW, Pinedo HM, Workman P, Schwartsmann G: EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. Eur J Cancer 29A:898–906, 1993
Bailey SM, Suggett N, Walton MI, Workman P: Structure-activity relationships for DT-diaphorase reduction of hypoxic cell directed agents: Indoloquinones and diaziridinyl benzoquinones. Int J Radiat Oncol Biol Phys 22:649–653, 1992
Bailey SM, Friedlos F, Knox RJ, Workman P: Bioreductive activation of indoloquinone EO9: Involvement of DT-diaphorase and DNA crosslinking. Ann Oncol 3:185, 1992
Robertson N, Stratford IJ, Houlbrook S, Carmichael J, Adams GE: The sensitivity of human tumour cells to quinone bioreductive drugs: What role for DT-diaphorase? Biochem Pharmacol 44:409–412, 1992
Walton MI, Bibby MC, Double JA, Plumb JA, Workman P: DT-diaphorase activity correlates with sensitivity to the indoloquinone EO9 in mouse and human colon carcinomas. Eur J Cancer 28A:1597–1600, 1992
Davignon JP, Slack JA, Beijnen JH, Vezin WR, Schoemaker TJ: EORTC/CRC/NCI guidelines for the formulation of investigational cytotoxic drugs. Eur J Cancer Oncol 24:1535–1538, 1988
International Conference on Harmonisation (ICH). Impurities in new drug substances. Draft 6, March 15, 1994
Cyr TD, Lawrence RC, Lovering EG: Survey of chlorinated hydrocarbons and other organic volatile impurities in captopril raw materials and tablets. Pharm Res 9:1224–1226, 1992
United States Pharmacopeia XXII. Organic volatile impurities 467:2927–2929, 1990
Residual solvents. Pharmeuropa 2:142–146, 1990
Oostveen EA, Speckamp WN: Mitomycin analogs I. Indoloquinones as (potential) bisalkylating agents. Tetrahedron 43:255–262, 1987
Speckamp WN, Oostveen EA: Indoloquinone compounds. U.S. Patent No. 5,079,257, 1992
Kinugawa M, Arai H, Nishikawa H, Sakaguchi A, Ogasa T, Tomioka S, Kasai M: Facile synthesis of the key intermediate of EO9 via the formation of the indole skeleton using the Nenitzescu reaction. J Chem Soc, Perkin Trans 21:2677–2678, 1995
De Vries JD, Winkelhorst J, Underberg WJM, Henrar REC, Beijnen JH: A systematic study on the chemical stability of the novel indoloquinone antitumour agent EO9. Int J Pharm 100:181–188, 1993
Taylor WG, Remers WA: Structure and stereochemistry of some 1,2-disubstitued mitosenes form solvolysis of mitomycin C and mitomycin A. J Med Chem 18:307–311, 1975
Beijnen JH, Lingeman H, Van Munster HA, Underberg WJM: Mitomycin antitumor agents: a review of physicochemical and analytical properties as well as stability. J Pharm Biomed Anal 4:275–295, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jonkman-de Vries, J.D., Kettenes-van den Bosch, J.J., Henrar, R.E.C. et al. Purity determinations in the bulk drug of the novel indoloquinone antitumor agent EO9. Invest New Drugs 14, 181–191 (1996). https://doi.org/10.1007/BF00210789
Issue Date:
DOI: https://doi.org/10.1007/BF00210789